clinical trial · NCT05337137
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
Bristol-Myers Squibb·phase2·completed·n = 82
Carcinoma, HepatocellularRelatlimabNivolumabBevacizumabPlacebo
brief summary
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
started
May 5, 2022
primary completion
Jul 5, 2025
completion
Nov 18, 2025
last updated
Oct 14, 2026
official title
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol